Noneczematous Contact Reactions

Goon, Anthony Teik‐Jin; Goh, C. J.

doi:10.1007/3-540-31301-x_21

Cited by 13 publications

(12 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, a reaction that becomes stronger until day 3 (crescendo) does by itself not prove an allergic etiology, as such reactions may also be elicited by irritants such as (low-dose) sodium lauryl sulfate (0.25 % in aqueous solution) [70]. In very rare cases, non-eczematous test reactions may be observed, including lymphomatoid, lichenoid, erythema multiforme-like, and granulomatous reactions [71].…”

Section: Strong Consensus (100 %)mentioning

confidence: 99%

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

Mahler

Nast

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board‐certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed‐type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physicians, nursing staff as well as patient representatives. The systematic methodological approach and appraisal of evidence upon which the recommendations are based are outlined in a separate method report that also contains evidence tables. The guidelines address general aspects of patch testing as well as medicolegal issues. The recommendations given relate to topics such as the indication for patch testing, informed patient consent, as well as the choice of test substances, test chambers and test site, duration of exposure, reading times and interpretation of test reactions. Furthermore, recommendations are provided with respect to endogenous and exogenous factors, specific patient groups (children, pregnant women, immunosuppressed individuals) as well as possible risks and adverse events associated with patch testing using contact allergens. Note: This publication is part 1 of the short version of the S3 guidelines for “Epicutaneous patch testing using contact allergens and drugs” (registry no. 013 – 018; date: March 20, 2019; valid until December 31, 2021). Part 2 of the short version will be published in the next issue. The long version of these guidelines can be accessed at http://www.awmf.org. The method report is available as online publication (https://www.awmf.org/leitlinien/detail/ll/013-018.html) and contains the evidence tables in its appendix.

show abstract

Section: Strong Consensus (100 %)mentioning

confidence: 99%

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

Mahler

Nast

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Erythema multiforme‐like reaction, also called urticarial papular and plaque eruption, is an uncommon non‐eczematous clinical variant of allergic contact dermatitis; its pathogenesis is unknown. Many allergens have been reported as causes of erythema multiforme‐like reactions, such as different woods and plants, topical medicines, metals, and chemicals such as p ‐phenylenediamine (1). Erythema multiforme‐like reactions have not been associated with topical vitamin K 1 or vitamin K 1 oxide exposure thus far.…”

mentioning

confidence: 99%

Erythema multiforme‐like reaction resulting from vitamin K₁ oxide (phytomenadione epoxide)

et al. 2017

View full text Add to dashboard Cite

“…EEM‐like eruption is a rare manifestation that occurs a few days after an allergic contact dermatitis (ACD) from diverse substances (4). Lesions are papules and plaques with a target‐like appearance that appear at acral sites and/or at distant sites of the ACD.…”

Section: Discussionmentioning

confidence: 99%

Erythema multiforme‐like eruption due to an irritant contact dermatitis from a glyphosate pesticide

Heras-Mendaza

Casado-Fariñas²,

Paredes-Gascón

et al. 2008

Contact Dermatitis

View full text Add to dashboard Cite

Noneczematous Contact Reactions

Cited by 13 publications

References 103 publications

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

Erythema multiforme‐like reaction resulting from vitamin K₁ oxide (phytomenadione epoxide)

Erythema multiforme‐like eruption due to an irritant contact dermatitis from a glyphosate pesticide

Contact Info

Product

Resources

About

Noneczematous Contact Reactions

Cited by 13 publications

References 103 publications

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

Erythema multiforme‐like reaction resulting from vitamin K1 oxide (phytomenadione epoxide)

Erythema multiforme‐like eruption due to an irritant contact dermatitis from a glyphosate pesticide

Contact Info

Product

Resources

About

Erythema multiforme‐like reaction resulting from vitamin K₁ oxide (phytomenadione epoxide)